The wider picture
The BA.3.2 variant, also known as “Cicada,” is a descendent of the BA.3 omicron subvariant that emerged in 2022. First identified in South Africa in November 2024, this variant carries approximately 70 to 75 mutations in its spike protein, raising concerns about its transmissibility and potential impact on vaccine efficacy.
Common symptoms associated with the Cicada variant include cough, fever or chills, sore throat, congestion, shortness of breath, loss of smell or taste, fatigue, headache, and gastrointestinal issues such as diarrhea or vomiting. Current evidence suggests that BA.3.2 does not cause more severe illness compared to earlier variants, with most cases appearing mild to moderate, resembling flu-like illness, particularly among vaccinated individuals.
Health experts, including Dr. Adolfo García-Sastre, emphasize that there is no evidence that BA.3.2 is causing more severe disease or hospitalizations in countries where it has become widespread. Most cases remain mild and can be managed at home with rest and hydration. Symptoms linked to the Cicada variant are largely consistent with previous COVID-19 strains, with no new or unusual signs reported so far.
Vaccines are expected to provide strong protection against severe disease, even if breakthrough infections occur. However, some health professionals caution that the current COVID-19 vaccines may not be as effective against the Cicada variant due to its multiple mutations. As a result, health authorities are actively monitoring the BA.3.2 variant due to its rising presence, which has been detected in over 20 countries and is currently on the rise in the United States, with cases reported in 25 states.
Health experts recommend that individuals stay up to date with vaccinations and take precautions in crowded settings to mitigate the spread of the variant. The Cicada variant primarily spreads through respiratory droplets and close contact in crowded or poorly ventilated spaces, similar to previous strains of the virus.
As the situation develops, health authorities are likely to continue monitoring the variant closely. Observers expect that increased public health measures may be implemented if the variant’s spread leads to a significant rise in cases or hospitalizations. However, for now, the symptoms and severity of the Cicada variant appear manageable, and the public is encouraged to remain vigilant.
Details remain unconfirmed regarding the long-term implications of the Cicada variant on public health. As research continues, health officials will provide updates on the variant’s characteristics and the effectiveness of current vaccines against it.
